-Parties: The applicants included AstraZeneca Canada Inc. and KuDOS Pharmaceuticals Limited. The respondent was Cipla Ltd.

-Subject Matter: This is a patent infringement action before the Federal Court brought under the Patented Medicines (Notice of Compliance) Regulations concerning Canadian Patent No. 2,737,400, relating to the drug LYNPARZA® (olaparib). The Plaintiffs allege infringement of the patent by Cipla's proposed generic product, CIPLA-OLAPARIB, while Cipla denies infringement and pleads that the patent is invalid on grounds including obviousness, overbreadth, insufficiency of disclosure, and lack of utility. The case is ongoing.

-Date: The hearing was set on July 22, 2026.

-Venue: This was a federal case before the Federal Court.

-Amount: No financial award was specified.